Treatment of CML Patients With Imatinib and Hydroxyurea (CML2004)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clinical Trial

— CML2004  

Official title:

Treatment of CML Patients With Imatinib and Hydroxyurea

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02480608
• Other study ID #: 68
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: June 10, 2015
• Last updated: June 23, 2015
• Start date: April 2004
• Est. completion date: May 2013

Study information

• Verified date: June 2015
• Source: University of Leipzig
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Ethics Commission
• Study type: Interventional

Clinical Trial Summary

The study will test the tolerability and efficacy of the combination therapy Imatinib/Hydroxyurea (HU) in patients with chronic myeloid leukemia (CML) in first chronic phase (CP1) newly diagnosted or failing interferon-based therapy.

Description:

The protocol consists of a part 1, a phase I study that will enrol 20 patients, with the goal to determine the safety of the combination as well as the maximal tolerated dose. If the toxicity of the combination is acceptable, up to 200 more patients may be recruited and randomized to receive either Imatinib/HU or Imatinib alone (part 2).

Patients who meet the inclusion criteria will be started on 400 mg Imatinib daily. In part 1 of the protocol, the dose of HU will be increased by 500 mg at 3-weekly intervals until the maximal tolerated dose has been reached. In part 2 of the study, patients will be randomized to receive either the combination or Imatinib monotherapy.

Hematological and cytogenetic response will be evaluated at 3-months intervals during the first year, and at 6 months' intervals thereafter. Primary endpoints for part 1 are dose-limiting toxicity and maximal tolerated dose. Primary endpoints for part 2 are the rates of major and complete molecular response at 6, 12 and 18 months, respectively.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 113
• Est. completion date: May 2013
• Est. primary completion date: August 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Ph-positive CML in CP1, newly diagnosed or resistant (hematologic or cytogenetic) or intolerant to interferon-based therapy

2. Age = 18 years

3. Negative pregnancy test

4. Low- and intermediate risk patients younger than 45 with an HLA (Human Leukocyte Antigen) -matched sibling donor and medically fit to undergo allografting should be included only after they have been adequately counselled about the potential risk (of disease progression) associated with delaying the allograft

5. Informed consent

Exclusion Criteria:

1. Objective signs of disease progression beyond CP1 defined as

• bone marrow or peripheral blood blasts > 15% and/or

• blasts + promyelocytes = 30% and/or

• peripheral blood basophils = 20% and/or

• platelets < 100/nl and/or

• chromosomal abnormalities in addition to the Ph chromosome

2. Findings suggestive of extramedullary involvement

3. Any severe and uncontrolled medical condition

4. Previous treatment with Imatinib (only part 2 of the study)

5. History of non-compliance

6. Simultaneous inclusion in other studies

Important note: previous treatment with Imatinib only is not an exclusion criterion for part 1 of the study.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Leukemia, Myelogenous, Chronic, BCR-ABL Positive
• Leukemia, Myeloid

Intervention

Drug:
• Imatinib

• Hydroxyurea

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University of Leipzig

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	number of participants with complete molecular response as a measure of efficacy	complete molecular response is achieved if BCR-ABL (breakpoint cluster region-Abelson murine leukemia) transcripts became undetectable	18 months	No